BVI Medical has gained FDA approval for the FineVision HP, the world’s first trifocal intraocular lens for cataract surgery. The approval allows the company to expand coverage in the intraocular lens (IOL) market and, more specifically, the multifocal IOL market. The FineVision HP patented design offers vision at far, intermediate and near distances providing an advantage to current intraocular lenses on the market. Although BVI Medical makes up a small portion of the IOL market, the FDA approval provides a compelling launch point for expansion in the space, says GlobalData, a leading data and analytics company.

According to GlobalData, the global IOL market was worth $4.6 billion in 2024 and is projected to reach $5.6 billion in 2034, with a compound annual growth rate (CAGR) of 2.1%. Meanwhile, the multifocal IOL market was worth $820.5 million in 2024 and is estimated to reach $977.3 million in 2034, with a CAGR of 1.8%.

Aidan Robertson, Medical Analyst at GlobalData, comments: “The FDA approval could present a substantial opportunity for BVI Medical as it attempts to establish itself in the IOL market. Given the clear benefits of a trifocal intraocular lens, interest in or preference for BVI Medical’s product is expected to increase compared to competitor products.”

BVI Medical remains a very small player in the IOL market, with large players being Alcon, Johnson & Johnson and Bausch Health, which account for 35.6%, 15.7% and 7.5% of the market, respectively. Although it is unlikely that the overall dynamics of the IOL market will change because of this development, it is possible that BVI Medical could utilize this momentum to become a more significant player in IOL.

Robertson continues: “The IOL market is estimated to continue to grow at a steady rate due to an aging population, which is increasing the prevalence of vision loss and thus creating further demand of eye care procedures. Additionally, more government investment in eye care facilities, advancements in research and technology, and growing awareness of vision related conditions are expected to be major drivers of this growth. Some barriers to the growth may be the reduced accessibility of these procedures in developing countries as well as the lack of skilled ophthalmologists globally.”

Robertson concludes: “Assuming BVI Medical focuses on market strategies such as partnerships with leading cataract surgeons and specialty centers, robust surgeon training and patient education, and strategic collaborations with payors and distributors to increase adoption, the company is expected to capture meaningful share in the IOL space in the future.”